Identification and evaluation of a new tumor cell-binding peptide, FROP-1

Journal of Nuclear Medicine

Volumn 48, Issue 6, 2007, Pages 965-972

  Zitzmann, Sabine ^a,b,d   Krämer, Susanne ^b   Mier, Walter ^b   Hebling, Ulrike ^a,b   Altmann, Annette ^a,b   Rother, Axel ^c   Berndorff, Dietmar ^d   Eisenhut, Michael ^a   Haberkorn, Uwe ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^d BAYER PHARMA AG   (Germany)

Author keywords

Mammary carcinoma; Peptide; Phage display; Thyroid carcinoma; Tumor targeting

Indexed keywords

IODINE 131; PEPTIDE; PEPTIDE FROP 1; PEPTIDE FROP 1 I 131; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ARTICLE; BINDING COMPETITION; BREAST CARCINOMA; CANCER CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG BINDING; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BINDING; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; TUMOR CELL; UMBILICAL VEIN; UTERINE CERVIX CARCINOMA; VASCULAR ENDOTHELIUM;

ADENOCARCINOMA, FOLLICULAR; ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; IODINE RADIOISOTOPES; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PEPTIDE LIBRARY; RADIOPHARMACEUTICALS; THYROID NEOPLASMS; TISSUE DISTRIBUTION;

EID: 34250379459     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.106.036699     Document Type: Article

References (20)

1. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol. 2004;183:249-256.
2. Gruning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG. Retinoic acid for redifferentiation of thyroid cancer: does it hold its promise? Eur J Endocrinol. 2003;148:395-402.
3. 90Y-DOTATOC in patients with medullary thyroid carcinomas. Cancer Biother Radiopharm. 2004;19:65-71.
4. Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med. 2005;46(suppl):67S-75S.
5. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabeled peptides for tumour therapy: current status and future directions-plenary lecture at the EANM 2002. Eur J Nucl Med Mol Imaging. 2003;30:463-469.
6. Reubi JC, Waser B. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas. Int J Cancer. 1996;67:644-647.
7. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors. Cancer Res. 1997;57:1377-1386.
8. Behe M, Behr TM. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies. Biopolymers. 2002;66:399-418.
9. Smith CJ, Volkert WA, Hoffman TJ. Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. Nucl Med Biol. 2005;32:733-740.
10. Brans B, Linden O, Giammarile F, Tennvall J, Punt C. Clinical applications of newer radionuclide therapies. Eur J Cancer. 2006;42:994-1003.
11. Brissette R, Prendergast JK, Goldstein NI. Identification of cancer targets and therapeutics using phage display. Curr Opin Drug Discov Devel. 2006;9:363-369.
12. Ruoslahti E. Drug targeting to specific vascular sites. Drug Discov Today. 2002;7:1138-1143.
13. Oyama T, Sykes KF, Samli KN, Minna JD, Johnston SA, Brown KC. Isolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagents. Cancer Lett. 2003;202:219-230.
14. Ninck S, Reisser C, Dyckhoff G, Helmke B, Bauer H, Herold-Mende C. Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck. Int J Cancer. 2003;106:34-44.
15. Schmidt K, Hoffend J, Altmann A, et al. Transfer of the sFLT-1 gene in Morris hepatoma results in decreased growth and perfusion and induction of genes associated with stress response. Clin Cancer Res. 2005;11:2132-2140.
16. Eisenhut M, Mier W. Radioiodination chemistry and radioiodinated compounds. In: Vértes A, Nagy S, Klencsár Z, eds. Handbook of Nuclear Chemistry. Vol 4. Boston, MA: Kluver Academic Publishers; 2003:257-278.
17. Kuhnast B, Bodenstein C, Haubner R, et al. Targeting of gelatinase activity with a radiolabeled cyclic HWGF peptide. Nucl Med Biol. 2004;31:337-344.
18. George AJ, Lee L, Pitzalis C. Isolating ligands specific for human vasculature using in vivo phage selection. Trends Biotechnol. 2003;21:199-203.
19. Nanus DM. Of peptides and peptidases: the role of cell surface peptidases in cancer. Clin Cancer Res. 2003;9:6307-6309.
20. Wester HJ, Kessler H. Molecular targeting with peptides or peptide-polymer conjugates: just a question of size? J Nucl Med. 2005;46:1940-1945.